Alnylam: 18-Month Results from Phase 3 in ATTR Amyloidosis with Cardiomyopathy

 

• Continued Treatment with Patisiran in Open-Label Extension Period Showed Evidence of Sustained Benefit across Measures of Functional Capacity and Health Status and Quality of Life, as well as Cardiac Stress and Injury, through 18 Months
• Safety Profile Consistent with that Observed in 12-Month Double-Blind Period, with No New Safety Findings

https://www.biospace.com/article/releases/alnylam-presents-18-month-results-from-the-apollo-b-phase-3-study-of-patisiran-in-patients-with-attr-amyloidosis-with-cardiomyopathy/